HLVX vs. KYTX, EXAI, ITOS, ADPT, VALN, HUMA, CRGX, RGNX, CABA, and ALEC
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Kyverna Therapeutics (KYTX), Exscientia (EXAI), iTeos Therapeutics (ITOS), Adaptive Biotechnologies (ADPT), Valneva (VALN), Humacyte (HUMA), CARGO Therapeutics (CRGX), REGENXBIO (RGNX), Cabaletta Bio (CABA), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Kyverna Therapeutics (NASDAQ:KYTX) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.
HilleVax received 5 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users.
In the previous week, Kyverna Therapeutics had 3 more articles in the media than HilleVax. MarketBeat recorded 14 mentions for Kyverna Therapeutics and 11 mentions for HilleVax. Kyverna Therapeutics' average media sentiment score of 0.51 beat HilleVax's score of -0.05 indicating that HilleVax is being referred to more favorably in the news media.
Kyverna Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 196.88%. HilleVax has a consensus target price of $29.00, suggesting a potential upside of 100.14%. Given HilleVax's higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than HilleVax.
18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 71.1% of HilleVax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
HilleVax's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.
Kyverna Therapeutics has higher revenue and earnings than HilleVax.
Summary
Kyverna Therapeutics beats HilleVax on 7 of the 11 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
